Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropocamptide - ProMore Pharma

X
Drug Profile

Ropocamptide - ProMore Pharma

Alternative Names: LL-37

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karolinska Institute
  • Developer ProMore Pharma
  • Class Anti-infectives; Antiulcers; Peptides
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Inflammation mediator modulators; Keratinocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Leg ulcer

Most Recent Events

  • 24 Feb 2021 Phase-II development is ongoing in Poland and Sweden (Topical) (ProMore Pharma pipeline, February 2021)
  • 05 Oct 2018 9250670: updated KDM and created development lines
  • 01 Oct 2018 Phase-II clinical trials in Leg ulcer in Poland (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top